- Home
- IVA vs RLMD Comparison
IVA vs RLMD Comparison
Compare IVA & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IVA
- RLMD
- Stock Information
- Founded
- IVA 2011
- RLMD 2004
- Country
- IVA France
- RLMD United States
- Employees
- IVA N/A
- RLMD N/A
- Industry
- IVA Biotechnology: Pharmaceutical Preparations
- RLMD Biotechnology: Pharmaceutical Preparations
- Sector
- IVA Health Care
- RLMD Health Care
- Exchange
- IVA Nasdaq
- RLMD Nasdaq
- Market Cap
- IVA 117.3M
- RLMD 110.6M
- IPO Year
- IVA 2020
- RLMD N/A
- Fundamental
- Price
- IVA $2.51
- RLMD $2.75
- Analyst Decision
- IVA Strong Buy
- RLMD Hold
- Analyst Count
- IVA 4
- RLMD 2
- Target Price
- IVA $14.00
- RLMD $7.50
- AVG Volume (30 Days)
- IVA 28.6K
- RLMD 126.6K
- Earning Date
- IVA 09-25-2024
- RLMD 11-07-2024
- Dividend Yield
- IVA N/A
- RLMD N/A
- EPS Growth
- IVA N/A
- RLMD N/A
- EPS
- IVA N/A
- RLMD N/A
- Revenue
- IVA $20,652,523.00
- RLMD N/A
- Revenue This Year
- IVA N/A
- RLMD N/A
- Revenue Next Year
- IVA $361.78
- RLMD N/A
- P/E Ratio
- IVA N/A
- RLMD N/A
- Revenue Growth
- IVA N/A
- RLMD N/A
- 52 Week Low
- IVA $1.53
- RLMD $1.88
- 52 Week High
- IVA $4.75
- RLMD $7.22
- Technical
- Relative Strength Index (RSI)
- IVA 45.32
- RLMD 23.58
- Support Level
- IVA $2.52
- RLMD $2.96
- Resistance Level
- IVA $2.77
- RLMD $3.43
- Average True Range (ATR)
- IVA 0.13
- RLMD 0.21
- MACD
- IVA -0.03
- RLMD -0.07
- Stochastic Oscillator
- IVA 0.00
- RLMD 1.60
About IVA Inventiva S.A. American Depository Shares
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.